NRX Pharmaceuticals (NRXP) Notes Payables (2019 - 2026)

NRX Pharmaceuticals (NRXP) has 7 years of Notes Payables data on file, last reported at $8.8 million in Q1 2026.

• On a quarterly basis, Notes Payables fell 11.02% year-over-year to $8.8 million in Q1 2026; TTM through Mar 2026 was $8.8 million, a 11.02% decrease from a year earlier, with the FY2025 full-year figure at $12.3 million, up 118.19% from the prior year.
• Notes Payables for Q1 2026 stood at $8.8 million, down from $12.3 million in the prior quarter.
• Over the last five years, Notes Payables for NRXP reached as high as $12.3 million in Q4 2025 and fell as low as $17000.0 in Q4 2023.
• Historically, Notes Payables has averaged $5.1 million across 5 years, with a median of $3.8 million in 2024.
• Across the five-year window, Notes Payables tumbled 99.92% in 2022 and soared 37792.31% in 2025, its largest moves.
• Year by year, Notes Payables stood at $37000.0 in 2022, then sank by 54.05% to $17000.0 in 2023, then jumped by 33070.59% to $5.6 million in 2024, then surged by 118.19% to $12.3 million in 2025, then retreated by 28.75% to $8.8 million in 2026.
• Per Business Quant data, the three most recent Notes Payables figures were $8.8 million in Q1 2026, $12.3 million in Q4 2025, and $9.9 million in Q3 2025.